Summary: Individuals with high baseline circulating levels of naturally occurring anti-NMDAR1 antibodies had a 25% lower risk of developing post-deployment depressive symptoms and a 22% lower risk of PTSD symptoms following a lifetime history of TBI.
Mechanistic mouse models revealed that antibody isotype size drives functional divergence: while small IgG isotypes penetrate synaptic clefts and impair memory (as seen in anti-NMDAR encephalitis), large, naturally occurring IgM isotypes selectively block extrasynaptic NMDA receptors that mediate excitotoxic injury after TBI, providing long-lasting neuroprotection.
Key Facts:
- Psychiatric Resilience Biomarker: Active-duty Marines in the highest quartile for circulating anti-NMDAR1 antibodies exhibited 25% lower depression scores and 22% lower PTSD symptom scores following TBI compared to those in the lowest quartile.
- Symptom-Specific Protection: Higher antibody levels protected against moderate-to-severe depression and PTSD and correlated with lower post-deployment psychiatric medication use, but showed no association with generalized anxiety symptoms.
- Long-Term Serum Stability: Anti-NMDAR1 antibodies remained detectable in serum for over 12 months, indicating that elevated expression functions as an enduring biological trait rather than a transient acute-phase reaction.
- Isotype Size Determines Pathology vs. Protection: Preclinical experiments showed that small IgG antibodies enter the synaptic cleft, driving cognitive dysfunction similar to autoimmune encephalitis. In contrast, larger IgM isotypes cannot fit into the synapse and instead bind to outer, extrasynaptic NMDA receptors.
- Inhibition of Excitotoxic Injury: Traumatic brain injury triggers pathological glutamate release that hyperactivates extrasynaptic NMDA receptors, causing secondary neuronal injury. By shielding these extrasynaptic sites, large IgM antibodies blunt excitotoxic cascades in a manner analogous to long-acting ketamine.
Source: UCSD
Every year, an estimated 20 million people worldwide sustain a concussion or other traumatic brain injury (TBI), which leads to a two- to four-fold increase in the risk of depression, anxiety and post-traumatic stress disorder (PTSD). Yet not everyone who experiences a TBI goes on to develop psychiatric symptoms.
Now, researchers at University of California San Diego School of Medicine and Veterans Affairs San Diego Healthcare System have identified an antibody (immune system protein) that could make people more resilient to these conditions.
They found that active-duty U.S. Marines with higher levels of the naturally-occurring anti-NMDAR1 antibody had a significantly lower risk of developing depression and PTSD symptoms following a TBI than those with lower levels of the antibody.
Anti-NMDAR1 targets NMDA receptors, key proteins responsible for storing new information and forming memories in the brain. The antibody is known to be involved in a rare brain disease called anti-NMDAR encephalitis, leading to memory deficits and neurological distress among other symptoms.
However, the study, published in Molecular Psychiatry, provides evidence that natural anti-NMDAR1 may act differently and serve a protective role in the brain.
The researchers analyzed blood samples and clinical psychiatric assessments collected from 1,025 Marines before and after a seven-month combat deployment to Afghanistan between 2011 and 2013. They found:
- Among participants with a lifetime history of TBI, those in the top quarter for natural anti-NMDAR1 antibody levels had about 25% lower depression symptom scores and 22% lower PTSD symptom scores after deployment than those with lower levels.
- These participants were also significantly less likely to report moderate-to-severe depression and they used fewer psychiatric medications after returning from deployment.
- These antibodies were detectable in blood for more than one year, suggesting that having high levels of these antibodies could be a relatively long-term trait.
- No association was found between anti-NMDAR1 levels and anxiety, suggesting these antibodies are associated with specific kinds of psychiatric symptoms.
The analysis was part of the Marine Resiliency Study II, a long-term research project investigating the factors that contribute to heightened risk for — or resilience to — PTSD.
“We were excited to find that a naturally-occurring immune marker could act almost like a built-in protective factor against some of the most disabling consequences of brain injury,” said co-senior author Victoria B. Risbrough, PhD, professor and vice chair of academic affairs in the Department of Psychiatry at UC San Diego School of Medicine and VA Research Career Scientist at VA San Diego Healthcare System. “If we can understand how these antibodies work, it may open a new path toward identifying who is most at risk after a TBI, and eventually, toward new ways to intervene.”
One hypothesis for the antibody’s protective effect is that natural anti-NMDAR1 antibodies found in Marines are of a type called IgM, which are too large to fit into synapses — the tiny gaps between brain cells where chemical signals are transmitted. Instead, this version may only latch on to receptors outside of that gap. Because these outer receptors are primary drivers of brain damage after a TBI, being blocked by IgM anti-NMDAR1 may shield the brain from further injury.
In a previous study, the research team tried to mimic psychiatric symptoms of human anti-NMDAR encephalitis in mice. They found that the mice carrying anti-NMDAR1 antibodies in their blood exhibited impaired cognitive function. However, their antibodies were of a much smaller “IgG” version than the naturally-occurring IgM antibodies found in Marines — small enough, in fact, to fit into the synaptic gaps. There is evidence that the smaller IgG version of anti-NMDAR1 may cause memory deficits in humans.
“We suspected that size difference determines whether an antibody reaches the receptors involved in brain injury versus the ones needed for everyday brain function,” said co-senior author Xianjin Zhou, associate professor of psychiatry at UC San Diego School of Medicine and faculty member at VA Mental Illness Research and Clinical Center. “When we tested that idea directly in mice, it held up: the smaller IgG antibodies impaired memory, while the larger IgM antibodies appeared to protect it.”
Ketamine, an FDA-approved treatment for depression and PTSD, is thought to work by blocking the same type of receptor, But unlike ketamine’s short-lived effects, naturally-occurring anti-NMDAR1 appears to persist in the blood for a year or longer.
However, the authors caution that these findings are correlational, and more research needs to be done to determine if natural anti-NMDAR1 antibodies truly play a protective role following TBI.
Additional co-authors on the study include: Melonie N. Vaughn, Jenna M. DeWit and Dewleen Baker at UC San Diego; Dean T. Acheson, Susan B. Powell, Caroline M. Nievergelt at UC San Diego and VA San Diego Healthcare System; and Kate A. Yurgil at Loyola University. Disclosures: Zhou is the inventor on a provisional patent filing by the University of California San Diego.
Funding: The study was funded, in part, by the National Institutes of Health (grant R01NS135620) and the U.S. Department of Veterans Affairs.
